NCT04712721: Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 & αvβ5 Integrins

NCT04712721
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Early Phase 1
Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patients must have at least one newly diagnosed brain metastasis that has not been resected or irradiated, or has been irradiated & progressed.
Exclusions: 
https://ClinicalTrials.gov/show/NCT04712721

Comments are closed.

Up ↑